Key regulators of Alzheimer’s disease: Network biology and in silico analysis with acetylcholinesterase and glutamate inhibitors
Gene & Protein in Disease · 30.04.2026 · 5 (2) · 026050003
DOI: 10.36922/gpd026050003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gene & Protein in Disease, online erschienen am 30.04.2026. Verfasst von Sayantan Das.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a complex, progressive neurodegenerative disorder driven by both genetic and environmental factors, with hallmark features including amyloid-β plaques and neurofibrillary tangles. Despite substantial research, the majority of currently licensed medications are still symptomatic, highlighting the need for multi-target and network-based treatment approaches. This study employed a systems biology approach to identify important regulatory proteins implicated in AD development and to assess their interaction patterns with approved glutamate and cholinesterase inhibitors. A protein–protein interaction network was developed using the 85 overlapping genes identified when AD-associated genes were selected from six significant biomedical databases. Seven major regulators were identified using centrality and hub analyses, including APP, APOE, BDNF, VEGFA, PSEN1, CASP1, and NOTCH1. Their participation in axon formation, signal transduction, neuroinflammatory processes, and neurodegenerative pathways was revealed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. The binding affinities of donepezil, galantamine, rivastigmine, and memantine toward these targets were evaluated by molecular docking using AutoDock Vina. While APP demonstrated relatively weaker affinities, BDNF demonstrated the strongest overall binding interactions, especially with donepezil. Memantine showed significant binding to PSEN1, indicating that amyloidogenic processes may be indirectly modulated. These results demonstrate the usefulness of integrated computational techniques in identifying new therapeutic interaction networks and support a multi-target pharmacological paradigm. This study offers a systems-level basis for medication repurposing and precision intervention strategies in AD, although additional experimental validation is needed.
Zitieren
APA
Das, S. (2026). Key regulators of Alzheimer’s disease: Network biology and in silico analysis with acetylcholinesterase and glutamate inhibitors. Gene & Protein in Disease, 5(2), 026050003. https://doi.org/10.36922/gpd026050003
Vancouver
Das S. Key regulators of Alzheimer’s disease: Network biology and in silico analysis with acetylcholinesterase and glutamate inhibitors. Gene & Protein in Disease. 2026;5(2):026050003. doi:10.36922/gpd026050003
BibTeX
@article{Das2026,
author = {Das, Sayantan},
title = {Key regulators of Alzheimer’s disease: Network biology and in silico analysis with acetylcholinesterase and glutamate inhibitors},
journal = {Gene & Protein in Disease},
year = {2026},
volume = {5},
number = {2},
pages = {026050003},
doi = {10.36922/gpd026050003}
}
EUVIMED